Prot #NU 16H08: Phase II study of PET-directed frontline therapy with pembrolizumab and AVD for patients with classical Hodgkin lymphoma

Project: Research project

StatusActive
Effective start/end date8/10/178/10/20

Funding

  • Merck Sharp & Dohme Corp. (Prot #NU 16H08)